OR WAIT null SECS
A propensity-matched real-world cohort study of 12,739 patients with atopic dermatitis (AD) presented at the Revolutionizing Atopic Dermatitis (RAD) 2026 Conference finds dupilumab (Dupixent) is associated with significantly reduced risk of new gastrointestinal and endocrine immune-mediated inflammatory diseases (IMIDs), but modestly increased risk of new dermatologic IMIDs, primarily psoriasis, over 3 years.1
At the same time, a companion case report from RAD 2026 illustrates an emerging clinical pattern: geriatric-onset atopic dermatitis refractory to dupilumab, in which S. aureus dysbiosis may sustain inflammation despite IL-4/IL-13 pathway blockade, suggesting a role for mechanistically distinct therapies.
"Clinicians should consider cutaneous microbiome dynamics when evaluating biologic non-response," the case report author, Josephine Hai, MD, of UC Davis, concluded. "The transition to nemolizumab in this dupilumab-refractory patient highlights the importance of mechanistically diverse biologic options in difficult-to-treat geriatric AD."
Geriatric-onset AD first appears in elderly adults without prior atopy. Age-related immune changes (inflammaging), altered skin barrier function, and microbiome dysbiosis may contribute to atypical presentations and variable therapeutic responses, including possible refractoriness to biologic therapy.
Using TriNetX to access de-identified electronic health records from 132 million patients across 72 US healthcare organizations, researchers identified 12,754 adult atopic dermatitis patients who received dupilumab between 2017 and 2026. After 1:1 propensity score matching on demographics, tobacco use, obesity, skin infections, and use of steroids and immunomodulatory agents, 2 cohorts of 12,739 each were compared over 3 years.
Dupilumab-treated patients had a significantly increased risk of new dermatologic IMIDs (relative risk [RR], 1.193; 95% CI, 1.016-1.400), driven primarily by psoriasis (RR, 1.238; 95% CI, 1.036-1.479).
Conversely, dupilumab was associated with significantly lower risk of gastrointestinal IMIDs (RR, 0.57; 95% CI, 0.356-0.915) and endocrine IMIDs (RR, 0.541; 95% CI, 0.370-0.791). No significant differences were found for new rheumatologic or musculoskeletal or ophthalmic IMIDs.
The authors noted the findings are consistent with dupilumab's mechanism: blocking IL-4 and IL-13 attenuates type 2 inflammation across organs, but paradoxical psoriasiform dermatitis following dupilumab has been previously documented in case series and pharmacovigilance data.
A separate case report included as a poster at the meeting described a 77-year-old male with no prior atopy history who developed generalized pruritic eczema at age 70. Biopsy confirmed spongiotic dermatitis; malignancy (including mycosis fungoides) was excluded. Despite 2 years of dupilumab 300 mg every 2 weeks plus topical therapy, the patient had persistent pruritus and intermittent flares.
Two separate short courses of amoxicillin-clavulanate in November 2025 and March 2026 produced significant improvement in both itch and rash, which recurred after each antibiotic course ended. The clinical pattern raised suspicion for S. aureus microbiome dysbiosis as a driver of disease persistence independent of IL-4/IL-13 blockade.
Dupilumab was discontinued and nemolizumab (Nemluvio), an anti-IL-31 receptor alpha monoclonal antibody approved December 2024, was initiated in April 2026, targeting the neuroimmune itch-inflammation axis rather than type 2 cytokines. At 6 weeks, the patient reported itch improvement with occasional rash flares. The case underscores the diagnostic complexity of geriatric-onset atopic dermatitis and the need for mechanistically diverse options.
Related Content:
